Risk stratification in primary sclerosing cholangitis: it’s time to move on from replicating imperfection and break the glass ceiling

Research output: Contribution to journalEditorial

Authors

Colleges, School and Institutes

Abstract

Primary sclerosing cholangitis (PSC) represents the greatest unmet need in modern hepatology, given its ill-defined aetiology, critical absence of medical therapy, and the fact that liver transplantation remains the only life-saving intervention for patients. Although rare, PSC now accounts for 10–15% of all liver transplant activity in European liver transplant programmes, and is now the lead indication for transplantation in Nordic countries.
However, rates of progression vary, and accurately predicting the disease course is of relevance to clinical practice and interventional trial design.
Patient expectations are also rising, with a feeling that doctors must be able to tell them if they are at risk, if so in what way, and with a reasonable degree of confidence.





Bibliographic note

Article in press. Online version available 9 September 2019. https://doi.org/10.1016/j.jhep.2019.08.013 Author ORCID Id: 0000-0002-4009-8087

Details

Original languageEnglish
Pages (from-to)867-870
Number of pages4
JournalJournal of Hepatology
Volume71
Issue number5
Early online date9 Sep 2019
Publication statusPublished - 1 Nov 2019

Keywords

  • Primary sclerosing cholangitis, PSC, Amsterdam Oxford PSC Score, UK PSC Risk score, prognostic model, clinical trial, biomarker